Camp4 Therapeutics (CAMP) Other Non-Current Liabilities (2023 - 2026)
Camp4 Therapeutics (CAMP) posted Other Non-Current Liabilities of $30000.0 for Q1 2026, up 3.45% sequentially from $29000.0 in Q4 2025, and up 1400.0% YoY from $2000.0 in Q1 2025.
Camp4 Therapeutics (CAMP) Other Non-Current Liabilities (2023 - 2026) Analysis & Trends
Camp4 Therapeutics has reported Other Non-Current Liabilities for 4 years, with the latest figure at $30000.0 in Q1 2026.
- Quarterly Other Non-Current Liabilities rose 1400.0% year-over-year to $30000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $30000.0 (up 1400.0% YoY) and the FY2025 annual result came in at $29000.0, down 59.72% from the prior year.
- Other Non-Current Liabilities grew to $30000.0 in Q1 2026 per CAMP's latest filing, from $29000.0 in the prior quarter.
- Over five years, Other Non-Current Liabilities peaked at $16.7 million in Q3 2025 and troughed at $2000.0 in Q4 2023.
- A 4-year average of $2.1 million and a median of $15500.0 in 2023 frame the typical range for Other Non-Current Liabilities.
- The widest YoY moves for Other Non-Current Liabilities: up 836500.0% in 2025, down 59.72% in 2025.
- Over 4 years, Other Non-Current Liabilities stood at $2000.0 in 2023, then soared by 3500.0% to $72000.0 in 2024, then slumped by 59.72% to $29000.0 in 2025, then grew by 3.45% to $30000.0 in 2026.
- According to Business Quant data, Other Non-Current Liabilities over the past three periods registered $30000.0, $29000.0, and $16.7 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Camp4 Therapeutics | 282.48 Mn | 282.48 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 71.88 Mn |
| Mar 31, 2026 | 30,000.00 |
| Dec 31, 2025 | 29,000.00 |
| Sep 30, 2025 | 16.73 Mn |
| Jun 30, 2025 | 2,000.00 |
| Mar 31, 2025 | 2,000.00 |
| Dec 31, 2024 | 72,000.00 |
| Sep 30, 2024 | 2,000.00 |
| Dec 31, 2023 | 2,000.00 |